Ramy G. Seddik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ramy G. Seddik has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Azza A. Shoukry
Inorganic Chemistry Division Chemistry Department Faculty of Science Cairo University Giza Egypt
3 shared publications- Fatma B. Rashidi
Chemistry Department,Biochemistry Division, Faculty of Science, Cairo University, Giza, Egypt
3 shared publications Doaa S. Salah‐Eldin
Biochemistry Division Chemistry Department Faculty of Science Cairo University Giza Egypt
2 shared publicationsFatma B. Rashidi
2 shared publicationsAhmed I. Elwakil
Faculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, Egypt
1 shared publicationAreej W. El-Sayed
Biotechnology Department, Faculty of Science, Cairo University, Giza, Egypt
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 25478
Glycoconjugate strategy for GLUT-driven curcumin delivery and anticancer activity in breast cancer cells
Selective targeting of cancer cells is a critical strategy in anticancer therapy, and the overexpression of glucose transporters (GLUTs) in malignant cells provides an attractive avenue for achieving this selectivity. In this study, we report the synthesis and biological evaluation of glycoconjugate vanadyl complexes as GLUT-directed anticancer agents against breast cancer. A Schiff base ligand (CG) was synthesized through the condensation of curcumin (C) and glucosamine (G), followed by complexation with vanadyl to form [VO(CG)₂]·5H₂O. The synthesized compounds were comprehensively characterized by elemental analysis, MS, NMR, FT-IR, TGA, molar conductance, and magnetic susceptibility measurements. Spectroscopic and computational studies confirmed that the ligand coordinates in a bidentate chelating mode via the azomethine nitrogen and the enolic oxygen. Biological evaluation in MCF-7 breast cancer cells included cytotoxicity assays, molecular docking, DNA-binding studies, and quantitative gene expression analysis. Both compounds exhibited cytotoxic activity, with the CG ligand showing the highest potency (IC₅₀ = 7.51 ± 0.12 μg/mL or 14.2 μM). Notably, co-treatment with the GLUT inhibitor quercetin significantly increased the IC₅₀ value, suggesting the involvement of GLUT-mediated cellular uptake. Molecular docking studies indicated favorable binding affinity toward GLUT, while DNA-binding experiments demonstrated interaction with DNA. Treatment of MCF-7 cells with the glycoconjugate ligand induced DNA damage, modulated the expression of cell cycle- and apoptosis-related genes, and promoted apoptosis. Flow cytometric analysis demonstrated that the glycoconjugate significantly arrested MCF-7 cells in the S-phase (49.40% vs 22.22% in control). This finding is consistent with impaired cell cycle progression and may be associated with the observed DNA interaction. Quantitative real-time PCR analysis of the CG compound revealed significant upregulation of BAX and CDKN1A (p21) ( p ≤ 0.05) and pronounced upregulation of STK11 (LKB1) ( p ≤ 0.001), suggesting activation of the AMPK signaling pathway and a metabolic stress response. Overall, the glycoconjugate ligand induces apoptosis and cell cycle arrest through oxidative and metabolic stress mediated by AMPK–STK11 signaling, highlighting its potential as a GLUT-targeted chemotherapeutic agent for breast cancer treatment.
- 14 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 25478
Open AccessGlycoconjugate strategy for GLUT-driven curcumin delivery and anticancer activity in breast cancer cells
Selective targeting of cancer cells is a critical strategy in anticancer therapy, and the overexpression of glucose transporters (GLUTs) in malignant cells provides an attractive avenue for achieving this selectivity. In this study, we report the synthesis and biological evaluation of glycoconjugate vanadyl complexes as GLUT-directed anticancer agents against breast cancer. A Schiff base ligand (CG) was synthesized through the condensation of curcumin (C) and glucosamine (G), followed by complexation with vanadyl to form [VO(CG)₂]·5H₂O. The synthesized compounds were comprehensively characterized by elemental analysis, MS, NMR, FT-IR, TGA, molar conductance, and magnetic susceptibility measurements. Spectroscopic and computational studies confirmed that the ligand coordinates in a bidentate chelating mode via the azomethine nitrogen and the enolic oxygen. Biological evaluation in MCF-7 breast cancer cells included cytotoxicity assays, molecular docking, DNA-binding studies, and quantitative gene expression analysis. Both compounds exhibited cytotoxic activity, with the CG ligand showing the highest potency (IC₅₀ = 7.51 ± 0.12 μg/mL or 14.2 μM). Notably, co-treatment with the GLUT inhibitor quercetin significantly increased the IC₅₀ value, suggesting the involvement of GLUT-mediated cellular uptake. Molecular docking studies indicated favorable binding affinity toward GLUT, while DNA-binding experiments demonstrated interaction with DNA. Treatment of MCF-7 cells with the glycoconjugate ligand induced DNA damage, modulated the expression of cell cycle- and apoptosis-related genes, and promoted apoptosis. Flow cytometric analysis demonstrated that the glycoconjugate significantly arrested MCF-7 cells in the S-phase (49.40% vs 22.22% in control). This finding is consistent with impaired cell cycle progression and may be associated with the observed DNA interaction. Quantitative real-time PCR analysis of the CG compound revealed significant upregulation of BAX and CDKN1A (p21) ( p ≤ 0.05) and pronounced upregulation of STK11 (LKB1) ( p ≤ 0.001), suggesting activation of the AMPK signaling pathway and a metabolic stress response. Overall, the glycoconjugate ligand induces apoptosis and cell cycle arrest through oxidative and metabolic stress mediated by AMPK–STK11 signaling, highlighting its potential as a GLUT-targeted chemotherapeutic agent for breast cancer treatment.
- Open Access
- 17 March 2026
- Published by Springer Nature in Journal of Inorganic and Organometallic Polymers and Materials
Pyrazine-Platinum(II) Nanoparticles as a Potential Anticancer Agent: Synthesis, Binding Mechanisms, and Biological Profiling
Pyrazine, a naturally occurring heterocycle with established safety in food and pharmaceutical applications, is an attractive ligand for the design of platinum-based anticancer agents. In this study, a novel platinum(II) complex, [Pt(Pz) 2 Cl 2 ], was synthesized using pyrazine as a nitrogen-donor ligand. The complex was comprehensively characterized by molar conductivity, elemental analysis, FT-IR, 1 H-NMR, UV–Vis, mass spectrometry, thermal analysis, and magnetic susceptibility. X-ray diffraction confirmed its semicrystalline structure, and TEM revealed irregularly shaped nanoparticles with an average size of 15–20 nm. Biological studies demonstrated strong interaction with DNA, including groove binding and cleavage activity, supported by viscosity measurements and thermal denaturation assays. The complex also exhibited significant binding affinity to bovine serum albumin (BSA), indicating favorable transport and distribution in biological systems. In vitro cytotoxicity assays showed that [Pt(Pz) 2 Cl 2 ] exerted the strongest inhibitory effect on A549 lung cancer cells (IC 50 = 7.97 ± 0.03 µg/mL), followed by HCT-116 colon (IC 50 = 28.22 µg/mL) and HepG2 liver cancer cells (IC 50 = 53.02 µg/mL), while displaying markedly lower toxicity toward normal WI-38 fibroblasts (IC 50 = 235 µg/mL), reflecting selective cytotoxicity. Morphological and flow cytometric analyses confirmed that the complex effectively induces necrotic cell death in A549 cells at concentrations near its IC 50 . Computational studies, including DFT and molecular docking, provided insights into the electronic structure and protein-binding interactions of the complex, while ADME-Tox predictions indicated favorable pharmacokinetic behavior and compliance with drug-likeness rules. Collectively, these findings highlight [Pt(Pz) 2 Cl 2 ] as a promising platinum-based anticancer candidate and reinforce the potential of pyrazine ligands in developing next-generation anticancer therapeutics.
- 17 March 2026
- Published by Springer Nature in Journal of Inorganic and Organometallic Polymers and Materials
Open AccessPyrazine-Platinum(II) Nanoparticles as a Potential Anticancer Agent: Synthesis, Binding Mechanisms, and Biological Profiling
Pyrazine, a naturally occurring heterocycle with established safety in food and pharmaceutical applications, is an attractive ligand for the design of platinum-based anticancer agents. In this study, a novel platinum(II) complex, [Pt(Pz) 2 Cl 2 ], was synthesized using pyrazine as a nitrogen-donor ligand. The complex was comprehensively characterized by molar conductivity, elemental analysis, FT-IR, 1 H-NMR, UV–Vis, mass spectrometry, thermal analysis, and magnetic susceptibility. X-ray diffraction confirmed its semicrystalline structure, and TEM revealed irregularly shaped nanoparticles with an average size of 15–20 nm. Biological studies demonstrated strong interaction with DNA, including groove binding and cleavage activity, supported by viscosity measurements and thermal denaturation assays. The complex also exhibited significant binding affinity to bovine serum albumin (BSA), indicating favorable transport and distribution in biological systems. In vitro cytotoxicity assays showed that [Pt(Pz) 2 Cl 2 ] exerted the strongest inhibitory effect on A549 lung cancer cells (IC 50 = 7.97 ± 0.03 µg/mL), followed by HCT-116 colon (IC 50 = 28.22 µg/mL) and HepG2 liver cancer cells (IC 50 = 53.02 µg/mL), while displaying markedly lower toxicity toward normal WI-38 fibroblasts (IC 50 = 235 µg/mL), reflecting selective cytotoxicity. Morphological and flow cytometric analyses confirmed that the complex effectively induces necrotic cell death in A549 cells at concentrations near its IC 50 . Computational studies, including DFT and molecular docking, provided insights into the electronic structure and protein-binding interactions of the complex, while ADME-Tox predictions indicated favorable pharmacokinetic behavior and compliance with drug-likeness rules. Collectively, these findings highlight [Pt(Pz) 2 Cl 2 ] as a promising platinum-based anticancer candidate and reinforce the potential of pyrazine ligands in developing next-generation anticancer therapeutics.
- 11 September 2024
- Published by Wiley in Chemistry & Biodiversity
- Vol. 21 (10) , e202400415
Synthesis, Characterization, DNA Binding, Biological Significance, and Molecular Docking Approaches of a Palladium(II) Complex with Ciprofloxacin for More Efficient Therapy
To evaluate the biotransformation and the mechanism of binding as well as the biological impact of metal‐based‐ drugs involving Pd(II), known to have high potency and low toxicity for use as anticancer therapeutics, in the present study, a newly synthesized palladium (II) complex, [Pd(CPF)(OH2)2]2+ (where CPF is ciprofloxacin), has been synthesized and characterized and thoroughly evaluated for its antimicrobial properties. The interaction of the diaqua complex with CT‐DNA and BSA was studied through various techniques, including UV‐vis spectroscopy, thermal denaturation, viscometry, gel electrophoresis, ethanol precipitation, and molecular docking studies. The results indicate that the complex exhibits a robust binding interaction with CT‐DNA, possibly via minor groove binding and (or) electrostatic interactions. Furthermore, the complex displays good binding affinity towards BSA, indicating its potential as a target for DNA and BSA in biological media. The invitro cytotoxicity assay reveals that this complex can be classified as a promising cell growth inhibitor against MCF‐7, HT‐29, and A549. Thus, this newly synthesized palladium (II) complex is a promising candidate for further exploration as a potential anticancer therapeutic.
- 11 September 2024
- Published by Wiley in Chemistry & Biodiversity
- Vol. 21 (10) , e202400415
Synthesis, Characterization, DNA Binding, Biological Significance, and Molecular Docking Approaches of a Palladium(II) Complex with Ciprofloxacin for More Efficient Therapy
To evaluate the biotransformation and the mechanism of binding as well as the biological impact of metal‐based‐ drugs involving Pd(II), known to have high potency and low toxicity for use as anticancer therapeutics, in the present study, a newly synthesized palladium (II) complex, [Pd(CPF)(OH2)2]2+ (where CPF is ciprofloxacin), has been synthesized and characterized and thoroughly evaluated for its antimicrobial properties. The interaction of the diaqua complex with CT‐DNA and BSA was studied through various techniques, including UV‐vis spectroscopy, thermal denaturation, viscometry, gel electrophoresis, ethanol precipitation, and molecular docking studies. The results indicate that the complex exhibits a robust binding interaction with CT‐DNA, possibly via minor groove binding and (or) electrostatic interactions. Furthermore, the complex displays good binding affinity towards BSA, indicating its potential as a target for DNA and BSA in biological media. The invitro cytotoxicity assay reveals that this complex can be classified as a promising cell growth inhibitor against MCF‐7, HT‐29, and A549. Thus, this newly synthesized palladium (II) complex is a promising candidate for further exploration as a potential anticancer therapeutic.
- 14 November 2023
- Published by Wiley in Chemistry & Biodiversity
- Vol. 20 (12) , e202301170
Investigation on CT‐DNA and Protein Interaction of New Pd(II) Complexes Involving Ceftazidime and 3‐Amino‐1,2,3‐triazole: Synthesis, Characterization, Biological Impact, Anticancer Evaluation, and Molecular Docking Approaches
Two new palladium (II) complexes, [Pd(CAZ)(OH2)2]2+ (1) and [Pd(3‐AT)(OH2)2]2+ (2), (CAZ=ceftazidime, and 3‐AT=amitrole) were synthesized and studied for their potential as anticancer drugs with low toxicity and high potency. To fully characterize these complexes, we conducted elemental analysis and FT‐IR studies. Furthermore, we irradiated the complexes with Indian 60Co gamma rays and thoroughly evaluated their antimicrobial properties. Our results demonstrate that the inhibitory activity of complexes was significantly enhanced against (G+) bacteria and fungi. Additionally, we probed the complexes’ interaction with CT‐DNA and BSA using various techniques, including UV‐vis spectroscopy, thermal denaturation, viscometry, gel electrophoresis, and molecular docking studies. Our findings conclusively demonstrate that these complexes possess a strong binding interaction with CT‐DNA via minor groove binding and/or electrostatic interactions, as well as excellent binding affinity to BSA. Finally, we conducted a cytotoxicity assay that clearly indicates these complexes hold immense promise as cell growth inhibitors against MCF‐7 and HCT‐116.
- 14 November 2023
- Published by Wiley in Chemistry & Biodiversity
- Vol. 20 (12) , e202301170
Investigation on CT‐DNA and Protein Interaction of New Pd(II) Complexes Involving Ceftazidime and 3‐Amino‐1,2,3‐triazole: Synthesis, Characterization, Biological Impact, Anticancer Evaluation, and Molecular Docking Approaches
Two new palladium (II) complexes, [Pd(CAZ)(OH2)2]2+ (1) and [Pd(3‐AT)(OH2)2]2+ (2), (CAZ=ceftazidime, and 3‐AT=amitrole) were synthesized and studied for their potential as anticancer drugs with low toxicity and high potency. To fully characterize these complexes, we conducted elemental analysis and FT‐IR studies. Furthermore, we irradiated the complexes with Indian 60Co gamma rays and thoroughly evaluated their antimicrobial properties. Our results demonstrate that the inhibitory activity of complexes was significantly enhanced against (G+) bacteria and fungi. Additionally, we probed the complexes’ interaction with CT‐DNA and BSA using various techniques, including UV‐vis spectroscopy, thermal denaturation, viscometry, gel electrophoresis, and molecular docking studies. Our findings conclusively demonstrate that these complexes possess a strong binding interaction with CT‐DNA via minor groove binding and/or electrostatic interactions, as well as excellent binding affinity to BSA. Finally, we conducted a cytotoxicity assay that clearly indicates these complexes hold immense promise as cell growth inhibitors against MCF‐7 and HCT‐116.
- Open Access
- 15 May 2023
- Published by Elsevier in SSRN Electronic Journal
Synthesis, Characterization, DNA Binding, Biological Significance, and Molecular Docking Approaches of Pd(Ii) Complexes with Ceftazidime and 3-Amino-1,2,3-Triazole for More Efficient Therapeutic Purposes
To discover other new metal drugs as anticancer therapeutics with low toxicity and high potency, two new palladium (II) complexes of the general formula [Pd(CAZ)Cl2] (1) and [Pd(3-AT)Cl2] (2), (where CAZ is ceftazidime and 3-AT is amitrole) were synthesized and re-characterized by elemental analysis and FT-IR. The Pd(II) complexes were gamma-irradiated with a dose of 30 kGy using Indian 60Co gamma rays and characterized by FT-IR analysis. The inhibitory activity of both complexes before and after irradiation was evaluated against various Gram-positive (G+) and Gram-negative (G−) bacteria and fungi. The antimicrobial properties of both complexes were enhanced by gamma irradiation against (G+) bacteria and fungi. The interaction of the diaqua complexes with CT-DNA was investigated by UV–vis spectroscopy, thermal denaturation, viscometry, gel electrophoresis, and molecular docking studies. The calculated intrinsic binding constant (Kb) reveals strong binding interaction with CT-DNA. The binding of complexes is likely via minor groove binding and/or electrostatic interactions. Additionally, spectroscopic, and molecular docking studies analyzed complexes' interaction with BSA (bovine serum albumin). Both complexes also exhibited good binding affinity to BSA. Strong interactions with DNA and BSA suggest that the two complexes could be potential targets for DNA and BSA in biological media. Furthermore, the in vitro cytotoxicity of the complexes against MCF-7 (human breast adenocarcinoma) cell lines, HCT-116 (human colorectal carcinoma) cell lines, and normal HSF (human skin fibroblast) cell lines before and after irradiation were examined by MTT assay. Cytotoxicity assay indicates that the synthesized palladium (II) complexes could be classified as promising cell growth inhibitors against the tested cancer cell lines.
- 15 May 2023
- Published by Elsevier in SSRN Electronic Journal
Open AccessSynthesis, Characterization, DNA Binding, Biological Significance, and Molecular Docking Approaches of Pd(Ii) Complexes with Ceftazidime and 3-Amino-1,2,3-Triazole for More Efficient Therapeutic Purposes
To discover other new metal drugs as anticancer therapeutics with low toxicity and high potency, two new palladium (II) complexes of the general formula [Pd(CAZ)Cl2] (1) and [Pd(3-AT)Cl2] (2), (where CAZ is ceftazidime and 3-AT is amitrole) were synthesized and re-characterized by elemental analysis and FT-IR. The Pd(II) complexes were gamma-irradiated with a dose of 30 kGy using Indian 60Co gamma rays and characterized by FT-IR analysis. The inhibitory activity of both complexes before and after irradiation was evaluated against various Gram-positive (G+) and Gram-negative (G−) bacteria and fungi. The antimicrobial properties of both complexes were enhanced by gamma irradiation against (G+) bacteria and fungi. The interaction of the diaqua complexes with CT-DNA was investigated by UV–vis spectroscopy, thermal denaturation, viscometry, gel electrophoresis, and molecular docking studies. The calculated intrinsic binding constant (Kb) reveals strong binding interaction with CT-DNA. The binding of complexes is likely via minor groove binding and/or electrostatic interactions. Additionally, spectroscopic, and molecular docking studies analyzed complexes' interaction with BSA (bovine serum albumin). Both complexes also exhibited good binding affinity to BSA. Strong interactions with DNA and BSA suggest that the two complexes could be potential targets for DNA and BSA in biological media. Furthermore, the in vitro cytotoxicity of the complexes against MCF-7 (human breast adenocarcinoma) cell lines, HCT-116 (human colorectal carcinoma) cell lines, and normal HSF (human skin fibroblast) cell lines before and after irradiation were examined by MTT assay. Cytotoxicity assay indicates that the synthesized palladium (II) complexes could be classified as promising cell growth inhibitors against the tested cancer cell lines.
- Open Access
- 1 January 2017
- Published by Open Access Text Pvt, Ltd. in General Medicine Open
- Vol. 1 (2)
Can metal replacement increase the antitumor activity of azurin? (in vitro study)
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.
- 1 January 2017
- Published by Open Access Text Pvt, Ltd. in General Medicine Open
- Vol. 1 (2)
Open AccessCan metal replacement increase the antitumor activity of azurin? (in vitro study)
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.